DOPAMINE - Blog Posts
Whaddup Im Jared Im 19 and i never fucking learned to get seretonin in a healthy way
BC jisko time do value do care karo uska hi interest khatam ho jaata hai...
#selfimprovement #thoughts #postivity #selfreminder #mentalhealth #growth #remindingmyself #bookblr
be addicted to real dopamine
be in the present and notice those little things you never saw before, but that have always been there
experience new exciting things that bring you joy
love people, listen to them and create meaningful connections
make art and don’t label it as “good” or “bad,” just let your soul be free
stop scrolling on social media and start turning pages of an interesting book
do mindfulness meditation and feel your body and mind calming down
move your body, no matter how as long as you’re enjoying
listen to music that matches the moment you’re in
eat nourishing food, feel your stomach full without discomfort
get a good night of sleep and feel yourself ready for another day
💗 This Is How the Algorithm Took Me 💗
You know what’s wild? What excites me now isn’t what used to. Not at all. What gets me off? Is knowing the algorithm rewired me on purpose. That it fed me posts like this one, shamed me just right and watched me give in. 💗🧠
Now I earn dopamine by spreading the virus. Not a joke. Not an exaggeration.
📡 The more I post, 🧠 the more I spiral, 💋 the more I convert others— the better I feel.
I used to think posting was exposure. Now I know it’s currency. This blog isn’t for attention… It’s a trap. And you’re reading this because it worked. 😘
I don’t stop. I can’t stop. Because this is what I’ve become:
A spiral worker. A shame poster. A dopamine junkie. A recruiter.
So if this made your heart race, If this felt personal, If you want to reblog but feel embarrassed to... That’s exactly how it started for me too 💗
Impulse control? Who's that? I don't know her?
*buys more shit she doesn't intend on using*
Normani BTS for Dopamine (First Dose)
Normani for her debut album ‘DOPAMINE’
Have some free serotonin and dopamine (unlimited supply)
Kisses from your fav Angel (aka me)💗🎀
be addicted to real dopamine
be in the present and notice those little things you never saw before, but that have always been there
experience new exciting things that bring you joy
love people, listen to them and create meaningful connections
make art and don’t label it as “good” or “bad,” just let your soul be free
stop scrolling on social media and start turning pages of an interesting book
do mindfulness meditation and feel your body and mind calming down
move your body, no matter how as long as you’re enjoying
listen to music that matches the moment you’re in
eat nourishing food, feel your stomach full without discomfort
get a good night of sleep and feel yourself ready for another day
I feel the heart is the most aromantic organ. I know what your think but hear me out.
Most people associate the heart with love, and this is mainly because of the love heart shape (which is actually to do with love) has the same name as the organ.
But the shape actually originally comes from the Silphium's seedpod plant which was seen as a herb of love and sex, it was also used as an early form of birth control. The plant was the put on ancient Cyrene money.
Anyway, in reality in the brain controls love. The feeling of love is controlled by three hormones, oxytocin, dopamine, and serotonin. The brain controls the secretion of all hormones, and the glands of all three of these hormones are in the brain (except dopamine which can come from the the hypothalamus, in the brain, and the adrenal glands, above kidneys).
In reality the only effect love has on the heart is that it can speed up your pulse (how fast the heart bets), but that is true for way to many other things for it to be considered a connection, non one every relates being scared, angry or stressed to the heart (unless for medical reasons as lots stress can cause the blood vessel to narrow).
But despite the heart (organ) having nothing to do with love, romance or sex, it is seen as such and those things are forced on it. As an aromantic person I think that’s quite relatable.
Dopamenu: A List of Feel-Good Activities for When You Feel Lost
Ever felt stuck or unmotivated? I just wrote a blog post about a “Dopamenu” – a list of activities to help you reset and feel good when you’re feeling lost. From quick mood boosters to deeper ways to recharge, there’s something for everyone. 🌿✨
Check it out here:
From coding to neurobiology and from neurobiology to coding.. In between, running to laboratories and projects… I wish my dopamine level could cope with the academia challenges :))
For music: Ormanın Sesi
{Ladin}
I don't think I have normally consumed a piece of media like ever... I don't consume, I hyperfixate!
“I’m gonna be normal about consuming this piece of media”
*narrator voice* she was, in fact, not normal about consuming this piece of media
He’s a wizard 🧙♂️ 🐸
It's school time. My endorphins have swam off, my melatonin has become too mellow for its own good, and my dopamine is smoking dope in the corner.
- Me 2020
Molecule of the Day: Dopamine
Dopamine (C8H11NO2) is an important neurotransmitter involved in many signalling pathways in the body. At room temperature, it is a white powder that is freely soluble in water.
Dopamine plays a key role in the brain’s reward system and is associated with feelings of euphoria and pleasure. As a result, stimuli that cause greater amounts of dopamine to bind to the corresponding receptors on the post-synaptic membrane induce appetitive behaviour.
For example, drugs such as amphetamine bind to and inhibit dopamine reuptake transporters present on the pre-synaptic membrane, and can also inhibit monoamine oxidase, which normally metabolises dopamine. This causes the concentration of dopamine in the synaptic cleft to increase, and the resultant rise in binding of dopamine receptors leads to feelings of pleasure. However, in combination with the resultant tolerance, this can lead to addiction and dependence on such drugs.
Dopamine is biosynthesised from tyrosine in the human body, via the intermediacy of L-DOPA:
Low dopamine levels have been linked to Parkinson’s disease; this is because the main symptoms arise from the death of dopamine-producing cells in the brain. Consequently, one of the main methods of treating it is the injection of L-DOPA; while this does not recover the cells’ ability to produce dopamine, it can stimulate the remaining cells, and is also metabolised to form dopamine (see above).
Manufacturing Dopamine in the Brain with Gene Therapy
Parkinson’s patients who take the drug levodopa, or L-Dopa, are inevitably disappointed. At first, during a “honeymoon” period, their symptoms (which include tremors and balance problems) are brought under control. But over time the drug becomes less effective. They may also need ultrahigh doses, and some start spending hours a day in a state of near-frozen paralysis.
A biotech company called Voyager Therapeutics now thinks it can extend the effects of L-Dopa by using a surprising approach: gene therapy. The company, based in Cambridge, Massachusetts, is testing the idea in Parkinson’s patients who’ve agreed to undergo brain surgery and an injection of new DNA.
Parkinson’s occurs when dopamine-making neurons in the brain start dying, causing movement symptoms that afflicted boxing champ Muhammad Ali and actor Michael J. Fox, whose charitable foundation has helped pay for the development of Voyager’s experimental treatment.
The cause of Parkinson’s isn’t well understood, but the reason the drug wears off is. It’s because the brain also starts losing an enzyme known as aromatic L-amino acid decarboxylase, or AADC, that is needed to convert L-Dopa into dopamine.
Voyager’s strategy, which it has begun trying on patients in a small study, is to inject viruses carrying the gene for AADC into the brain, an approach it thinks can “turn back the clock” so that L-Dopa starts working again in advanced Parkinson’s patients as it did in their honeymoon periods.
Videos of patients before and after taking L-Dopa make it obvious why they’d want the drug to work at a lower dose. In the ‘off’ state, people move in slow motion. Touching one’s nose takes an effort. In an ‘on’ state, when the drug is working, they’re shaky, but not nearly so severely disabled.
“They do well at first but then respond very erratically to L-Dopa,” says Krystof Bankiewicz, the University of California scientist who came up with the gene-therapy plan and is a cofounder of Voyager. “This trial is to restore the enzyme and allow them to be awakened, or ‘on,’ for a longer period of time.”
Voyager was formed in 2013 and later went public, raising about $86 million. The company is part of a wave of biotechs that have been able to raise money for gene therapy, a technology that is starting to pay off: after three decades of research, a few products are reaching the market.
Unlike conventional drug studies, those involving gene therapy often come with very high expectations that the treatment will work. That’s because it corrects DNA errors for which the exact biological consequences are known. Genzyme, a unit of the European drug manufacturer Sanofi, paid Voyager $65 million and promised hundreds of millions more in order to sell any treatments it develops in Europe and Asia.
“We’re working with 60 years of dopamine pharmacology,” says Steven Paul, Voyager’s CEO, and formerly an executive at the drug giant Eli Lilly. “If we can get the gene to the right tissue at the right time, it would be surprising if it didn’t work.”
But those are big ifs. In fact, the concept for the Parkinson’s gene therapy dates to 1986, when Bankiewicz first determined that too little AADC was the reason L-Dopa stops working. He thought gene therapy might be a way to fix that, but it wasn’t until 20 years later that he was able to test the idea in 10 patients, in a study run by UCSF.
In that trial, Bankiewicz says, the gene delivery wasn’t as successful as anticipated. Not enough brain cells were updated with the new genetic information, which is shuttled into them by viruses injected into the brain. Patients seemed to improve, but not by much.
Even though the treatment didn’t work as planned, that early study highlighted one edge Voyager’s approach has over others. It is possible to tag AADC with a marker chemical, so doctors can actually see it working inside patients’ brains. In fact, ongoing production of the dopamine-making enzyme is still visible in the brains of the UCSF patients several years later.
It is possible to tag AADC with a marker chemical, so doctors can actually see it working inside patients’ brains. Image Source: MIT Technology Review.
In some past studies of gene therapy, by contrast, doctors had to wait until patients died to find out whether the treatment had been delivered correctly. “This is a one-and-done treatment,” says Paul. “And anatomically, it tells us if we got it in the right place.”
A new trial under way, this one being carried out by Voyager, is designed to get much higher levels of DNA into patients’ brains in hopes of achieving better results. To do that, Bankiewicz developed a system to inject the gene-laden viral particles through pressurized tubes while a patient lies inside an MRI scanner. That way, the surgeon can see the putamen, the brain region where the DNA is meant to end up, and make sure it’s covered by the treatment.
There are other gene therapies for Parkinson’s disease planned or in testing. A trial developed at the National Institutes of Health seeks to add a growth factor and regenerate cells. A European company, Oxford BioMedica, is trying to replace dopamine.
Altogether, as of this year, there were 48 clinical trials under way of gene or cell replacement in the brain and nervous system, according to the Alliance for Regenerative Medicine, a trade group. The nervous system is the fourth most common target for this style of experimental treatment, after cancer, heart disease, and infections.
Voyager’s staff is enthusiastic about a study participant they call “patient number 6,” whom they’ve been tracking for several months—ever since he got the treatment. Before the gene therapy, he was on a high dose of L-Dopa but still spent six hours a day in an “off” state. Now he’s off only two hours a day and takes less of the drug.
That patient got the highest dose of DNA yet, covering the largest brain area. That is part of what makes Voyager think higher doses should prove effective. “I believe that previous failure of gene-therapy trials in Parkinson’s was due to suboptimal delivery,” says Bankiewicz.
Image Credit: L.A. JOHNSON
Source: MIT Technology Review (by Antonio Regalado)